ESALF News and Press, Eisai Co Ltd From 05/15/24

2024-05-15 07:44:07 ET More on Biogen, Eisai Co., Ltd., etc. Biogen: Reasons To Be Cheerful After Upbeat Q1 Earnings Biogen: Don't Overthink This One Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade) Biogen says uptake for Alzheimer’s therapy...

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status TOKYO and CAMBRIDGE, Mass., May 15, 2024 - (JCN Newswire) - Eisai Co., Ltd. and...

Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures TOKYO, May 13, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received approval in China for the additional indication of its in-house disc...

2024-05-07 09:38:29 ET More on Eli Lilly Eli Lilly: Great Time To Divest Before It Potentially Crashes Eli Lilly Remains Expensive Here - Minimal Margin Of Safety Eli Lilly: Don't Overpay For Miracle Drugs Pharma R&D productivity seen improving for the fi...

2024-04-30 12:47:04 ET Summary Biogen Inc.'s Alzheimer therapy, Leqembi, is finally gaining traction with Q1 '24 sales of $19 million, nearly tripling Q4 revenues. The drug has faced challenges in gaining coverage and reimbursement, but it is expected to reach multi-billion dollar...

2024-04-24 08:03:47 ET More on Biogen Biogen Inc. (BIIB) Stifel 2024 Virtual CNS Days (Transcript) Biogen Inc. (BIIB) TD Cowen 44th Annual Health Care Conference - (Transcript) Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade) Bio...

2024-04-22 00:58:35 ET Summary The FDA has convened an advisory panel to discuss the safety and efficacy of Eli Lilly's anti-amyloid antibody drug donanemab. Approval of donanemab could have a modestly positive impact on LLY stock, while denial could lead to a substantial (but not...

Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) TOKYO, Apr 18, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Ba...

Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan TOKYO, Apr 17, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infu...

2024-04-16 15:31:20 ET More on Biogen, Eisai, etc. Biogen Inc. (BIIB) Stifel 2024 Virtual CNS Days (Transcript) Eisai: All About Lenvima And Leqembi Biogen Inc. (BIIB) TD Cowen 44th Annual Health Care Conference - (Transcript) GLP-1s benefit Parkinson’...